J3R-MC-YDAG - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes
EloralintideEloralintideEloralintidePlacebo to match LYEloralintide
Eligibility
Age group
65+ years, 18-64 years
Sex
Female, Male
Primary endpoint
Percent Change from Baseline in Body Weight [Time Frame: Baseline, Week 64
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.